Results 11 to 20 of about 1,518,675 (340)

COVID 19 and vaccine safety

Medycyna Ogólna i Nauki o Zdrowiu, 2021
Introduction and objective COVID-19 disease, caused by the SARS-CoV-2 virus, has been recognised as a pandemic by WHO since 11 March 2020.
Przemysław Raczkiewicz, Marcin Trojnar, Bartłomiej Zaremba, Natalia Śmiech   +3 more
doaj   +3 more sources

Vaccines for COVID-19 [PDF]

Clinical and Experimental Immunology, 2020
SummarySince the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been ...
Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.‐M., Pierce, B. F., Stirling, D. C., Wang, Z., Pollock, K. M.   +9 more
openaire   +3 more sources

COVID-19 vaccines and vaccine administration [PDF]

British Journal of Nursing, 2021
This article provides an overview of current COVID-19 vaccines available within the UK, including their mode of action, storage and handling. It outlines the recommendations on priority groups for vaccination and provides insight into the training recommendations for vaccinators.
Gordon, Charlotte, Porteous, Debbie, Unsworth, John   +2 more
openaire   +2 more sources

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

New England Journal of Medicine, 2021
Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting.
Noa Dagan, N. Barda, Eldad Kepten, O. Miron, Shay Perchik, M. Katz, M. Hernán, M. Lipsitch, B. Reis, R. Balicer   +9 more
semanticscholar   +1 more source

COVID-19 Vaccination and The Eye [PDF]

American Journal of Ophthalmology, 2022
To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events.Narrative literature review.The literature search was conducted in August 2021 using 4 electronic databases: MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic Reviews.
Michael T.M. Wang, Rachael L. Niederer, Charles N.J. McGhee, Helen V. Danesh-Meyer   +3 more
openaire   +2 more sources

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

New England Journal of Medicine, 2022
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current ...
N. Andrews, J. Stowe, Freja C M Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A. O’Connell, D. Simons, P. Blomquist, A. Zaidi, S. Nash, Nurin Iwani Binti Abdul Aziz, S. Thelwall, G. Dabrera, R. Myers, G. Amirthalingam, S. Gharbia, J. Barrett, R. Elson, S. Ladhani, N. Ferguson, M. Zambon, C. Campbell, K. Brown, S. Hopkins, M. Chand, M. Ramsay, J. Lopez Bernal   +30 more
semanticscholar   +1 more source

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

The Lancet, 2021
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials.
D. Logunov, I. Dolzhikova, D. Shcheblyakov, A. Tukhvatulin, O. Zubkova, A. Dzharullaeva, A. Kovyrshina, N. Lubenets, D. Grousova, A. Erokhova, A. G. Botikov, F. Izhaeva, O. Popova, T. Ozharovskaya, I. Esmagambetov, I. Favorskaya, D. Zrelkin, Daria V Voronina, D. Shcherbinin, A. Semikhin, Y. Simakova, E. Tokarskaya, D. Egorova, M. M. Shmarov, N. Nikitenko, V. Gushchin, E. Smolyarchuk, S. K. Zyryanov, S. Borisevich, B. Naroditsky, A. Gintsburg   +30 more
semanticscholar   +1 more source

COVID-19 Vaccines

Infectious Disease Clinics of North America, 2022
This article is a narrative review of the rapidly moving coronavirus disease 2019 vaccine field with an emphasis on clinical efficacy established in both randomized trials and postmarketing surveillance of clinically available vaccines. We review the major clinical trials that supported authorization for general use of the Janssen (Ad.26.CoV2), Pfizer ...
Hahn, William O., Wiley, Zanthia
openaire   +3 more sources

COVID-19 vaccines for children [PDF]

Science, 2021
Earlier this month, the US Centers for Disease Control and Prevention (CDC) recommended Pfizer’s COVID-19 messenger RNA (mRNA) vaccine for children between 5 and 11 years of age—that’s 28 million children. Yet surveys show that 42 to 66% of parents of these children are reluctant or opposed to seeking this protection.
Jeffrey S, Gerber, Paul A, Offit
openaire   +2 more sources

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Nature Communications, 2021
Identifying and understanding COVID-19 vaccine hesitancy within distinct populations may aid future public health messaging. Using nationally representative data from the general adult populations of Ireland (N = 1041) and the United Kingdom (UK; N ...
Jamie Murphy, F. Vallières, R. Bentall, M. Shevlin, O. McBride, T. Hartman, Ryan T McKay, K. Bennett, L. Mason, J. Gibson-Miller, L. Levita, Antón P. Martínez, T. Stocks, T. Karatzias, P. Hyland   +14 more
semanticscholar   +1 more source